Skip to main content
. 2022 Apr 11;82(8):1658–1668. doi: 10.1158/0008-5472.CAN-21-0626

Figure 2.

Figure 2. Bevacizumab treatment in MDA-MD-231 tumors changes systemic VEGF and hemoglobin levels, while influencing VEGF positivity in the responding tumors. Systemic levels of hVEGF (A) in the circulation are significantly reduced in responding mice but no change in mVEGF (B) is observed (Ctrl nmice = 5, Bev-NR nmice = 6, Bev-R nmice = 3). C, Responding mice also show a significant increase in systemic levels of biochemical hemoglobin (Ctrl nmice = 7, Bev-NR nmice = 8, Bev-R nmice = 2). D and E, hVEGF measured using IHC in the respective tumors shows a significant increase in positivity in the responders (Ctrl ntumors = 14, Bev-NR ntumors = 14, Bev-R ntumors = 5). Scale bars = 50 µm; P values are displayed from two-sided Student t tests except in D, where a Welch t test was performed because of unequal variances.

Bevacizumab treatment in MDA-MD-231 tumors changes systemic VEGF and hemoglobin levels, while influencing VEGF positivity in the responding tumors. A and B, Systemic levels of hVEGF (A) in the circulation are significantly reduced in responding mice but no change in mVEGF (B) was observed (Ctrl, nmice = 5; Bev-NR, nmice = 6; Bev-R, nmice = 3). C, Responding mice also showed a significant increase in systemic levels of biochemical hemoglobin (Ctrl, nmice = 7; Bev-NR, nmice = 8; Bev-R, nmice = 2). D and E, hVEGF measured using IHC in the respective tumors showed a significant increase in positivity in the responders (Ctrl, ntumors = 14, Bev-NR, ntumors = 14; Bev-R, ntumors = 5). Scale bars, 50 µm. P values are displayed from two-sided Student t tests except in D, where a Welch t test was performed because of unequal variances.